Aurinia Pharmaceuticals announced the acceptance of six abstracts at the American Society of Nephrology (ASN) Kidney Week 2024 highlighting the clinical importance of Aurinia’s product Lupkynis (voclosporin). Kidney Week takes place October 23-27 in San Diego, California.
Lupkynis is a second-generation calcineurin inhibitor with a dual mechanism of action, acting as an immunosuppressant through inhibition of T-cell activation and cytokine production and promoting podocyte stability in the kidney. It is used to treat adults with active lupus nephritis (LN).
New real-world baseline data from the ENLIGHT-LN registry provides a critical foundation for understanding the real-world effectiveness and usage patterns of Lupkynis and includes a subset of patients with high percentages of Black, Hispanic, and/or Latino patients, reflecting the larger population of LN in the United States and the communities disproportionately affected by lupus and LN.
Meanwhile, two new studies reveal the potential effects of Lupkynis on podocytes in LN and idiopathic nephrotic syndrome compared to older treatments. One study explored the impact of cyclosporine A, tacrolimus, and Lupkynis on podocyte cell biology and biomechanics, while another examined the effects of Lupkynis in a preclinical model of idiopathic nephrotic syndrome.
The Aurinia abstracts accepted at Kidney Week 2024 include:
- “Enlight-LN Registry: Baseline Demographics and Clinical Characteristics of an Initial Cohort of Patients Treated with Voclosporin for Lupus Nephritis in the United States” by Niloofar Nobakht, et al.
- “Disease Targeting Properties of Voclosporin in Renal Transplant and Lupus Nephritis Patients” by Simon Zhou, et al.
- “Immunologic Changes Over Time in Repeat Kidney Biopsies from the AURORA Studies of Voclosporin in Lupus Nephritis” by Samir V. Parikh, et al.
- “Integrative Systems Analyses Reveal Calcineurin Inhibitor-Mediated Control of Human Podocyte Biophysics and Physiology” by Jacob M. Wright, et al.
- “Voclosporin Ameliorates Proteinuria and Directly Protects Podocytes in a Model of Non-Inflammatory Glomerular Disease” by Yu Kamigaki, et al.
- “Characterization of Screening Patterns and Identification of Patients with Lupus Nephritis in a Community Rheumatology Setting” by Nehad Soloman, et al.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.